This interactive workshop is designed for biotech startups and draws on more than a decade of hVIVO's investor due diligence experience, incorporating insights gained from over 150 due diligence and gap analysis projects.
Participants will learn:
- How investors assess risks across drug development programmes.
- How strategic, regulatory, CMC, non-clinical, clinical, and translational development decisions can influence funding opportunities, valuation, and partnering potential.
- How proactive gap analyses can strengthen investor readiness, reduce perceived risk, and enhance asset value.
Through anonymised case studies, we will explore how development decisions that appear harmless or low-risk can unintentionally introduce hidden risks that emerge during investor due diligence and fundraising activities.
The workshop aims to help biotech start-ups view development decisions through the lens of the investor, equipping teams to anticipate due diligence challenges, address value-limiting gaps, and position their assets more effectively for fundraising, partnering, and future growth.
Workshop: Build Your Target Product Profile With Confidence
Build your Target Product Profile With Confidence For biotech and start‑up teams balancing innovation with speed, a ...
From Preclinical to Clinical: Essential Steps Toward First-In-Human Studies
Practical Solutions for Complex Drug Development The journey from concept to First‑In‑Human (FIH) trials is filled with ...
From Preclinical to Clinical: Essential Steps Toward First-In-Human Studies
Practical Solutions for Complex Drug Development The journey from concept to First‑In‑Human (FIH) trials is filled with ...